173 related articles for article (PubMed ID: 30883740)
1. IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.
Corrò C; Healy ME; Engler S; Bodenmiller B; Li Z; Schraml P; Weber A; Frew IJ; Rechsteiner M; Moch H
J Pathol; 2019 Jul; 248(3):377-389. PubMed ID: 30883740
[TBL] [Abstract][Full Text] [Related]
2. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.
Grépin R; Guyot M; Giuliano S; Boncompagni M; Ambrosetti D; Chamorey E; Scoazec JY; Negrier S; Simonnet H; Pagès G
Cancer Res; 2014 Feb; 74(3):873-83. PubMed ID: 24335961
[TBL] [Abstract][Full Text] [Related]
3. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.
Zhu YM; Webster SJ; Flower D; Woll PJ
Br J Cancer; 2004 Nov; 91(11):1970-6. PubMed ID: 15545974
[TBL] [Abstract][Full Text] [Related]
6. IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma.
Sharma I; Singh A; Siraj F; Saxena S
J Biomed Sci; 2018 Aug; 25(1):62. PubMed ID: 30086759
[TBL] [Abstract][Full Text] [Related]
7. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.
Ginestier C; Liu S; Diebel ME; Korkaya H; Luo M; Brown M; Wicinski J; Cabaud O; Charafe-Jauffret E; Birnbaum D; Guan JL; Dontu G; Wicha MS
J Clin Invest; 2010 Feb; 120(2):485-97. PubMed ID: 20051626
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-8/CXCR1 Signaling Contributes to the Progression of Pulmonary Adenocarcinoma Resulting in Malignant Pleural Effusion.
Chang YM; Huang WY; Yang SH; Jan CI; Nieh S; Lin YS; Chen SF; Lin YC
Cells; 2024 Jun; 13(11):. PubMed ID: 38891100
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
Liotti F; Collina F; Pone E; La Sala L; Franco R; Prevete N; Melillo RM
Stem Cells; 2017 Jan; 35(1):135-146. PubMed ID: 27577959
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
11. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases.
Chen L; Fan J; Chen H; Meng Z; Chen Z; Wang P; Liu L
Sci Rep; 2014 Aug; 4():5911. PubMed ID: 25081383
[TBL] [Abstract][Full Text] [Related]
12. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
13. Disrupting Inflammation-Associated CXCL8-CXCR1 Signaling Inhibits Tumorigenicity Initiated by Sporadic- and Colitis-Colon Cancer Stem Cells.
Fisher RC; Bellamkonda K; Alex Molina L; Xiang S; Liska D; Sarvestani SK; Chakrabarti S; Berg A; Jorgensen ML; Hatala D; Chen S; Aiello A; Appelman HD; Scott EW; Huang EH
Neoplasia; 2019 Mar; 21(3):269-281. PubMed ID: 30738331
[TBL] [Abstract][Full Text] [Related]
14. An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
Mishra A; Suman KH; Nair N; Majeed J; Tripathi V
Mol Biol Rep; 2021 Sep; 48(9):6551-6561. PubMed ID: 34426905
[TBL] [Abstract][Full Text] [Related]
15. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
16. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
17. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials.
Li A; Varney ML; Singh RK
Clin Cancer Res; 2001 Oct; 7(10):3298-304. PubMed ID: 11595728
[TBL] [Abstract][Full Text] [Related]
18. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.
Wang J; Hu W; Wang K; Yu J; Luo B; Luo G; Wang W; Wang H; Li J; Wen J
Int J Oncol; 2016 Apr; 48(4):1341-52. PubMed ID: 26847910
[TBL] [Abstract][Full Text] [Related]
19. The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma.
Ewington L; Taylor A; Sriraksa R; Horimoto Y; Lam EW; El-Bahrawy MA
Cytokine; 2012 Aug; 59(2):417-22. PubMed ID: 22626766
[TBL] [Abstract][Full Text] [Related]
20. Neurotensin signaling regulates stem-like traits of glioblastoma stem cells through activation of IL-8/CXCR1/STAT3 pathway.
Zhou J; Yi L; Ouyang Q; Xu L; Cui H; Xu M
Cell Signal; 2014 Dec; 26(12):2896-902. PubMed ID: 25200966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
